387 related articles for article (PubMed ID: 28756395)
1. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
[TBL] [Abstract][Full Text] [Related]
4. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.
Pollock KG; Kavanagh K; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Cruickshank M; Palmer TJ; Nicoll S; Donaghy M
Br J Cancer; 2014 Oct; 111(9):1824-30. PubMed ID: 25180766
[TBL] [Abstract][Full Text] [Related]
5. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
[TBL] [Abstract][Full Text] [Related]
6. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
8. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
[TBL] [Abstract][Full Text] [Related]
12. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
[TBL] [Abstract][Full Text] [Related]
13. Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions.
Russ SM; Brackney M; Meek J; Niccolai LM
Vaccine; 2019 Jul; 37(31):4262-4267. PubMed ID: 31248688
[TBL] [Abstract][Full Text] [Related]
14. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
15. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
[TBL] [Abstract][Full Text] [Related]
16. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation.
Palmer TJ; Kavanagh K; Cuschieri K; Cameron R; Graham C; Wilson A; Roy K
J Natl Cancer Inst; 2024 Jun; 116(6):857-865. PubMed ID: 38247547
[TBL] [Abstract][Full Text] [Related]
17. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
[TBL] [Abstract][Full Text] [Related]
18. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
Kann H; Hortlund M; Eklund C; Dillner J; Faust H
Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
[TBL] [Abstract][Full Text] [Related]
20. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
